Major vascular complications in essential thrombocythemia:: a study of the predictive factors in a series of 148 patients

被引:157
作者
Besses, C
Cervantes, F
Pereira, A
Florensa, L
Solé, F
Hernández-Boluda, C
Woessner, S
Sans-Sabrafen, J
Rozman, C
Montserrat, E
机构
[1] Univ Autonoma Barcelona, Hosp Mar, Unitat Hematol 1973, E-08003 Barcelona, Spain
[2] Univ Barcelona, Hosp Clin, IDIBAPS,Postgrad Sch Hematol Farreras Valenti, Dept Hematol, E-08007 Barcelona, Spain
关键词
essential thrombocythemia; thrombosis; vascular complications;
D O I
10.1038/sj.leu.2401270
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
To determine the clinicohematological factors predictive for the appearance of major vascular complications (MVC) in patients with essential thrombocythemia (ET), 148 consecutive such patients were retrospectively assessed for the development of MVC during a median follow-up of 58.5 months. Seventy-seven patients had vascular risk factors, and 37 a history of MVC at ET diagnosis. Forty-nine MVC were registered in 33 patients during the follow-up period. The actuarial probability of MVC was 27% at 6 years in the whole series, 35.6% for patients above 60 years, and 21.4% for patients younger than 60 years, whereas only one of the 36 patients younger than 45 years had MVC. At multivariate analysis, age >60 years, history of major ischemia and hypercholesterolemia were the variables associated with an increased MVC risk. These results suggest that all ET patients above 60 years should be treated, whereas in younger patients treatment decisions should be primarily based on the existence of risk factors for MVC.
引用
收藏
页码:150 / 154
页数:5
相关论文
共 43 条
[1]   ISCHEMIC STROKE AS FIRST MANIFESTATION OF ESSENTIAL THROMBOCYTHEMIA - REPORT OF 6 CASES [J].
ARBOIX, A ;
BESSES, C ;
ACIN, P ;
MASSONS, JB ;
FLORENSA, L ;
OLIVERES, M ;
SANSSABRAFEN, J .
STROKE, 1995, 26 (08) :1463-1466
[2]   Treatment strategies in essential thrombocythemia - A critical appraisal of various experiences in different centers [J].
Barbui, T ;
Finazzi, G ;
Dupuy, E ;
Kiladjian, JJ ;
Briere, J .
LEUKEMIA & LYMPHOMA, 1996, 22 :149-160
[3]  
BELLUCCI S, 1986, CANCER, V58, P2440, DOI 10.1002/1097-0142(19861201)58:11<2440::AID-CNCR2820581115>3.0.CO
[4]  
2-Y
[5]  
BRANDT L, 1995, EUR J HAEMATOL, V54, P21
[6]   THE INCIDENCE OF THROMBOTIC AND HEMORRHAGIC DISORDERS IN ASSOCIATION WITH EXTREME THROMBOCYTOSIS - AN ANALYSIS OF 129 CASES [J].
BUSS, DH ;
STUART, JJ ;
LIPSCOMB, GE .
AMERICAN JOURNAL OF HEMATOLOGY, 1985, 20 (04) :365-372
[7]  
COLOMBI M, 1991, CANCER-AM CANCER SOC, V67, P2926, DOI 10.1002/1097-0142(19910601)67:11<2926::AID-CNCR2820671136>3.0.CO
[8]  
2-3
[9]   HYDROXYUREA FOR PATIENTS WITH ESSENTIAL THROMBOCYTHEMIA AND A HIGH-RISK OF THROMBOSIS [J].
CORTELAZZO, S ;
FINAZZI, G ;
RUGGERI, M ;
VESTRI, O ;
GALLI, M ;
RODEGHIERO, F ;
BARBUI, T .
NEW ENGLAND JOURNAL OF MEDICINE, 1995, 332 (17) :1132-1136
[10]   INCIDENCE AND RISK-FACTORS FOR THROMBOTIC COMPLICATIONS IN A HISTORICAL COHORT OF 100 PATIENTS WITH ESSENTIAL THROMBOCYTHEMIA [J].
CORTELAZZO, S ;
VIERO, P ;
FINAZZI, G ;
DEMILIO, A ;
RODEGHIERO, F ;
BARBUI, T .
JOURNAL OF CLINICAL ONCOLOGY, 1990, 8 (03) :556-562